To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning

This study has been withdrawn prior to enrollment.
(the PI is no longer work at Hadassah)
Sponsor:
Collaborator:
Bayer
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00226512
First received: September 9, 2005
Last updated: April 7, 2011
Last verified: September 2005
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given